Michał Biśta

3.5k total citations · 1 hit paper
20 papers, 2.5k citations indexed

About

Michał Biśta is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Michał Biśta has authored 20 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 6 papers in Oncology and 3 papers in Organic Chemistry. Recurrent topics in Michał Biśta's work include Chemical Synthesis and Analysis (5 papers), Cancer-related Molecular Pathways (4 papers) and Microbial Natural Products and Biosynthesis (3 papers). Michał Biśta is often cited by papers focused on Chemical Synthesis and Analysis (5 papers), Cancer-related Molecular Pathways (4 papers) and Microbial Natural Products and Biosynthesis (3 papers). Michał Biśta collaborates with scholars based in United States, Germany and United Kingdom. Michał Biśta's co-authors include Tad A. Holak, Michael Sixt, Dieter E. Jenne, Dorothee Neukirchen, Zena Werb, Frank Bradke, Álvaro H. Crevenna, Roland Wedlich‐Söldner, Julia Riedl and Kai Kessenbrock and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Angewandte Chemie International Edition.

In The Last Decade

Michał Biśta

20 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lifeact: a versatile marker to visualize F-actin

2008 1.7k citations Julia Riedl, Álvaro H. Crevenna et al. Nature Methods profile →

Peers

Countries citing papers authored by Michał Biśta

Since Specialization

Citations

This map shows the geographic impact of Michał Biśta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michał Biśta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michał Biśta more than expected).

Fields of papers citing papers by Michał Biśta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michał Biśta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michał Biśta. The network helps show where Michał Biśta may publish in the future.

Co-authorship network of co-authors of Michał Biśta

This figure shows the co-authorship network connecting the top 25 collaborators of Michał Biśta. A scholar is included among the top collaborators of Michał Biśta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michał Biśta. Michał Biśta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CRISPR GUARD protects off-target sites from Cas9 nuclease activity using short guide RNAs 2020 ·Nature Communications ·Matthew A. Coelho, Étienne De Braekeleer, Mike Firth, Michał Biśta, Sebastian Łukasiak, Maria Emanuela Cuomo, Ben Taylor	58
2	Antibody fragments structurally enable a drug-discovery campaign on the cancer target Mcl-1 2019 ·Acta Crystallographica Section D Structural Biology ·Jakub Lupták, Michał Biśta, David I. Fisher, Liz Flavell, Ning Gao, (unknown), Steven L. Kazmirski, Tina Howard, Philip B. Rawlins, David Hargreaves	7
3	Positioning High-Throughput CETSA in Early Drug Discovery through Screening against B-Raf and PARP1 2018 ·SLAS DISCOVERY ·Joseph Shaw, Ian L. Dale, Paul Hemsley, Lindsey Leach, (unknown), Jonathan P. Orme, (unknown), A.J. Narvaez, Michał Biśta, Daniel Martinez Molina, Michael Dabrowski, Martin J. Main, Davide Gianni	31
4	Mapping the sugar dependency for rational generation of a DNA-RNA hybrid-guided Cas9 endonuclease 2017 ·Nature Communications ·(unknown), Michał Biśta, Matthew D. Newton, Anne U. Goeppert, Maria Emanuela Cuomo, Euan Gordon, (unknown), Jon Read, Jonathan D.J. Wrigley, David Rueda, Ben Taylor	54
5	Quantifying the relationship between inhibition of VEGF receptor 2, drug‐induced blood pressure elevation and hypertension 2017 ·British Journal of Pharmacology ·(unknown), (unknown), Michał Biśta, Matthew Skinner, Christopher M. Hardy, Haiyun Wang, Jerome T. Mettetal, Alexander R. Harmer	16
6	MTH1 Substrate Recognition—An Example of Specific Promiscuity 2016 ·PLoS ONE ·J. Willem M. Nissink, Michał Biśta, J. Breed, (unknown), Kevin J. Embrey, (unknown), (unknown)	19
7	Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival 2016 ·Journal of Medicinal Chemistry ·Jason G. Kettle, (unknown), Michał Biśta, J. Breed, Nichola L. Davies, (unknown), Shaun Fillery, Kevin M. Foote, Louise Goodwin, David R. Jones, Helena Käck, Alan Lau, J. Willem M. Nissink, Jon Read, James S. Scott, Ben Taylor, Graeme E. Walker, Lisa Wissler, Marta Wylot	100
8	Transient Protein States in Designing Inhibitors of the MDM2-p53 Interaction 2013 ·Structure ·Michał Biśta, Siglinde Wolf, Kareem Khoury, (unknown), Yijun Huang, (unknown), Marcelino Arciniega, Grzegorz M. Popowicz, Tad A. Holak, Alexander Dömlingꝉ	47
9	MDMX contains an autoinhibitory sequence element 2013 ·Proceedings of the National Academy of Sciences ·Michał Biśta, Miriana Petrovich, Alan R. Fersht	45
10	Domain–domain interactions in full-length p53 and a specific DNA complex probed by methyl NMR spectroscopy 2012 ·Proceedings of the National Academy of Sciences ·Michał Biśta, Stefan M.V. Freund, Alan R. Fersht	34
11	Enabling Large-Scale Design, Synthesis and Validation of Small Molecule Protein-Protein Antagonists 2012 ·PLoS ONE ·David Ryan Koes, Kareem Khoury, Yijun Huang, Wei Wang, Michał Biśta, Grzegorz M. Popowicz, Siglinde Wolf, Tad A. Holak, Alexander Dömlingꝉ, Carlos J. Camacho	79
12	On the Mechanism of Action of SJ-172550 in Inhibiting the Interaction of MDM4 and p53 2012 ·PLoS ONE ·Michał Biśta, David C. Smithson, (unknown), (unknown), Katarzyna Pustelny, Jaeki Min, Artur Piróg, (unknown), Michal Zdzalik, (unknown), Benedykt Władyka, Sylwia Kędracka–Krok, Michael A. Dyer, Grzegorz Dubin, R. Kiplin Guy	46
13	1,4‐Thienodiazepine‐2,5‐diones via MCR (I): Synthesis, Virtual Space and p53‐Mdm2 Activity 2010 ·Chemical Biology & Drug Design ·Yijun Huang, Siglinde Wolf, Michał Biśta, Lidio Meireles, Carlos J. Camacho, Tad A. Holak, Alexander Dömlingꝉ	50
14	Robust Generation of Lead Compounds for Protein–Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists 2010 ·Angewandte Chemie International Edition ·Anna Czarna, Barbara Beck, Stuti Srivastava, Grzegorz M. Popowicz, Siglinde Wolf, Yijun Huang, Michał Biśta, Tad A. Holak, Alexander Dömlingꝉ	113
15	Robust Generation of Lead Compounds for Protein–Protein Interactions by Computational and MCR Chemistry: p53/Hdm2 Antagonists 2010 ·Angewandte Chemie ·Anna Czarna, Barbara Beck, Stuti Srivastava, Grzegorz M. Popowicz, Siglinde Wolf, Yijun Huang, Michał Biśta, Tad A. Holak, Alexander Dömlingꝉ	21
16	Robust NMR Screening for Lead Compounds Using Tryptophan-Containing Proteins 2009 ·Journal of the American Chemical Society ·Michał Biśta, (unknown), (unknown), Alexander Dömlingꝉ, Tad A. Holak	26
17	Structural and functional characterization of SplA, an exclusively specific protease of Staphylococcus aureus 2009 ·Biochemical Journal ·(unknown), Katarzyna Pustelny, (unknown), Michał Biśta, Kevin T. Boulware, Henning R. Stennicke, Ida B. Thøgersen, Patrick S. Daugherty, Jan J. Enghild, Krzysztof Baczyński, Grzegorz M. Popowicz, Adam Dubin, Jan Potempa, Grzegorz Dubin	36
18	Enzymatic Activity of the Staphylococcus aureus SplB Serine Protease is Induced by Substrates Containing the Sequence Trp-Glu-Leu-Gln 2008 ·Journal of Molecular Biology ·Grzegorz Dubin, (unknown), (unknown), Katarzyna Pustelny, Grzegorz M. Popowicz, Michał Biśta, Tomasz Kantyka, Kevin T. Boulware, Henning R. Stennicke, Anna Czarna, (unknown), Patrick S. Daugherty, Ida B. Thøgersen, Jan J. Enghild, Nancy A. Thornberry, Adam Dubin, Jan Potempa	39
19	Lifeact: a versatile marker to visualize F-actin breakdown → 2008 ·Nature Methods ·Julia Riedl, Álvaro H. Crevenna, Kai Kessenbrock, (unknown), Dorothee Neukirchen, Michał Biśta, Frank Bradke, Dieter E. Jenne, Tad A. Holak, Zena Werb, Michael Sixt, Roland Wedlich‐Söldner	1702
20	A novel member of the thermolysin family, cloning and biochemical characterization of metalloprotease from Staphylococcus pseudintermedius. 2008 ·Acta Biochimica Polonica ·Benedykt Władyka, Michał Biśta, Artur J. Sabat, (unknown), (unknown), Waleria Hryniewicz, Adam Dubin	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact